WO2001026639A3 - Pharmaceutical composition of ateglinide and another antidiabeticagent - Google Patents

Pharmaceutical composition of ateglinide and another antidiabeticagent Download PDF

Info

Publication number
WO2001026639A3
WO2001026639A3 PCT/EP2000/009816 EP0009816W WO0126639A3 WO 2001026639 A3 WO2001026639 A3 WO 2001026639A3 EP 0009816 W EP0009816 W EP 0009816W WO 0126639 A3 WO0126639 A3 WO 0126639A3
Authority
WO
WIPO (PCT)
Prior art keywords
ateglinide
antidiabeticagent
another
pharmaceutical composition
treatment
Prior art date
Application number
PCT/EP2000/009816
Other languages
French (fr)
Other versions
WO2001026639A2 (en
Inventor
Marjorie Regan Gatlin
Michele Pongowski
Beth Dunning
Original Assignee
Novartis Ag
Novartis Erfind Verwalt Gmbh
Marjorie Regan Gatlin
Michele Pongowski
Beth Dunning
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Erfind Verwalt Gmbh, Marjorie Regan Gatlin, Michele Pongowski, Beth Dunning filed Critical Novartis Ag
Priority to AU11339/01A priority Critical patent/AU1133901A/en
Priority to EP00972695A priority patent/EP1218015A2/en
Publication of WO2001026639A2 publication Critical patent/WO2001026639A2/en
Publication of WO2001026639A3 publication Critical patent/WO2001026639A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Abstract

The invention relates to a combination which comprises nateglinide and (a) an antidiabetic phenylacetic acid derivative or (b) acarbose for simultaneous, separate or sequential use, in particular in the treatment of diseases, especially metabolic disorders; to a method of prevention, delay of progression or treatment of metabolic disorders, more especially diabetes, or a disease or condition associated with diabetes, and to a method of improving the bodily appearance of a warm-blooded animal.
PCT/EP2000/009816 1999-10-08 2000-10-06 Pharmaceutical composition of ateglinide and another antidiabeticagent WO2001026639A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU11339/01A AU1133901A (en) 1999-10-08 2000-10-06 Method of treating metabolic disorders
EP00972695A EP1218015A2 (en) 1999-10-08 2000-10-06 Pharmaceutical composition of nateglinide and another antidiabetic agent

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41530899A 1999-10-08 1999-10-08
US41530799A 1999-10-08 1999-10-08
US09/415,308 1999-10-08
US09/415,307 1999-10-08

Publications (2)

Publication Number Publication Date
WO2001026639A2 WO2001026639A2 (en) 2001-04-19
WO2001026639A3 true WO2001026639A3 (en) 2002-01-10

Family

ID=27022945

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/009816 WO2001026639A2 (en) 1999-10-08 2000-10-06 Pharmaceutical composition of ateglinide and another antidiabeticagent

Country Status (3)

Country Link
EP (1) EP1218015A2 (en)
AU (1) AU1133901A (en)
WO (1) WO2001026639A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2401356A1 (en) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Combination drug
CZ20023121A3 (en) * 2000-03-17 2003-05-14 Ajinomoto Co., Inc. Pharmaceutical preparations intended for treating diabetic complications and neuropathy and use of such preparations
CA2439063A1 (en) * 2001-03-12 2002-09-19 Novartis Ag Combination of nateglinide or repaglinide with at least one further antidiabetic compound
WO2003003971A2 (en) * 2001-06-20 2003-01-16 Merck Sante Use of antidiabetics for making a medicine with cicatrizing effect
CN1274668C (en) * 2002-03-11 2006-09-13 诺瓦提斯公司 Salts of nateglinide
ES2359910T3 (en) * 2002-05-28 2011-05-30 Ajinomoto Co., Inc. MEDICINAL COMPOSITION TO INHIBIT THE EXPRESSION OF ATP-CITRATE LIASA AND ITS USE.
WO2005092319A1 (en) * 2004-03-29 2005-10-06 Ranbaxy Laboratories Limited Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
CN101756971B (en) * 2008-10-09 2013-09-18 北京德众万全药物技术开发有限公司 Oral solid drug composition of metformin hydrochloride repaglinide
CN107106583B (en) * 2015-06-05 2021-04-13 台中荣民总医院 Pharmaceutical compositions comprising acarbose and their use for immunomodulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0749751A2 (en) * 1995-06-20 1996-12-27 Takeda Chemical Industries, Ltd. Pharmaceutical composition for use in tteatment of diabetes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0749751A2 (en) * 1995-06-20 1996-12-27 Takeda Chemical Industries, Ltd. Pharmaceutical composition for use in tteatment of diabetes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOMGARDEN Z.T.: "American diabetes association annual meeting, 1998: More on the treatment of type 2 diabetes.", DIABETES CARE, 22/2 (357-361)., February 1999 (1999-02-01), XP000997498 *
DUNNING B.E.: "Nateglinide: A glucose-sensitive insulinotropic agent that is chemically and pharmacologically distinct from the sulfonylureas.", CURRENT OPINION IN ENDOCRINOLOGY AND DIABETES, (1999) 6/SUPPL. 1 (S29-S31)., XP000997507 *
PERFETTI R ET AL: "NOVEL THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE 2 DIABETES", DIABETES/METABOLISM REVIEWS,US,WILEY, NEW YORK, NY, vol. 14, no. 3, 1998, pages 207 - 225, XP000908775, ISSN: 0742-4221 *

Also Published As

Publication number Publication date
WO2001026639A2 (en) 2001-04-19
AU1133901A (en) 2001-04-23
EP1218015A2 (en) 2002-07-03

Similar Documents

Publication Publication Date Title
WO2001021159A3 (en) Pharmaceutical composition of nateglinide and another antidiabetcagent
JP2007536277A5 (en)
WO2004028521A3 (en) Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
WO2002009690A3 (en) Pharmaceutical composition comprising a photochemotherapeutic agent and a mucoadhesive agent
AU2003248245A1 (en) Remedies for diseases caused by vascular contraction or dilation
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2001030381A3 (en) Use of csf-1 inhibitors
WO2002047668A3 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
MXPA03004349A (en) Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity.
WO2001009138A3 (en) Chemokine receptor antagonists and methods of use therefor
WO2003082260A3 (en) Tuberculosis treatment using pleuromutilin derivatives
WO2005053607A3 (en) Method for preventing hepatic encephalopathic episodes
EP1575573A3 (en) Agents and methods for treatment of disease by oligosaccharide targeting agents
WO2001026639A3 (en) Pharmaceutical composition of ateglinide and another antidiabeticagent
WO2003072030A3 (en) Methods for preventing or treating cardiac arrhythmia
AU2003291536A1 (en) Method for the diagnosis and treatment of vascular disease
AU2000265525A1 (en) Medicament for treating intestinal diseases
WO2003097050A3 (en) A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
WO2003094842A3 (en) Conjugates comprising central nervous system active drug
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
WO2005084695A3 (en) Use of carboxypeptidase g for combating antifolate toxicity
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
EP1133997A3 (en) Treatment of immune diseases with beta-interferon
AU4445201A (en) Method for administering insulin to the buccal region

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000972695

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000972695

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000972695

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP